Connect Biopharma’s total capital pool nears the US$200 million mark U.S.- and China-based clinical-stage biopharmaceutical company Connect Biopharma has completed a fundraise of US$115 million in a Series C round, the company announced in a statement yesterday. The round was led by U.S.-based multi-stage investment manager RA Capital Management, the statement said. Principal at RA […]

Xuanzhu Biopharmaceutical welcomes Chinese government’s State Development and Investment Corporation as an investor Xuanzhu Biopharmaceutical, a subsidiary of China-based pharmaceutical company Sihuan Pharmaceutical Holdings, has raised RMB800 million (approximately US$115.6 million) in its Series A round of financing, according to a statement by the company today. The funding was raised from Chinese state-owned investment company

Funding will be used to enhance R&D capacity and strengthen existing infrastructure Antengene Corporation, an innovative hematology and oncology-focused biopharmaceutical company, announced on July 20 that it had successfully closed US$97 million in Series C financing, to support ongoing drug development and preparations for potential commercialization.  The financing was led by Fidelity Management & Research

Citrine Medicine aims to develop an ecosystem for rare disease patients in China Citrine Medicine, a Chinese rare disease-focused therapeutics startup founded by Eight Roads, F-Prime Capital, and Vivo Capital, has raised $80 million in a Series A funding round, according to a press release on Monday. The latest financing round was led by Quan

Harbour BioMed takes its capital pool to well over US$300 million with this round Shanghai-based biotech startup Harbour BioMed has rounded off its Series C financing with a haul of US$102.8 million, the company announced in a statement today. Hudson Bay Capital led the round, with participation from OrbiMed, Country Garden VC, GTJA Investment Group,